AUTL News and Press, Autolus Therapeutics plc From 08/04/22

Autolus Therapeutics press release ( NASDAQ: AUTL ): Q2 GAAP EPS of -$0.46 misses by $0.13 . Cash at Q2 totaled $216.4 million, as compared to cash of $310.3 million at December 31, 2021. For further details see: Autolus Therapeutics GAAP EPS of -$0.46 misses...

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the second quarter ended June 30, 2022. ...

Autolus Therapeutics ( NASDAQ: AUTL ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.33 (vs. -$0.47 last year) and the consensus Revenue Estimate is $0.24M (-85.0% Y/Y). Over the last 3 months...

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL...

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlight...

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending William Blair’s Biotech Focus Conference 2022 a...

- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma - AUTO1/22 demonstrates encouraging and durable responses in children ineligible for commercial CAR T product - Obe-cel shows high level of sustained clinical activi...

LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be view...

LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending the Jefferies Healthcare Conference at the Marriott Mar...

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-cel: poster presentation in r/r primary CNS lymphoma - obe-cel: poster p...